Stereotaxis reports Q1 revenue $6.3M, net loss $5.9M; guides FY26 rev >$40M; MAGiC FDA approved, Robocath acquisition

Stereotaxis, Inc.

Revenue $6.3M vs $7.5M YoY; net loss $5.9M; cash $14.6M, no debt.
MAGiC catheter (FDA approved Jan) and Synchrony system (FDA cleared Apr) now in commercial use.
Definitive agreement to acquire Robocath, combining complementary robotic technologies.
Guides FY26 revenue >$40M, double-digit growth; Q3 and Q4 each >$10M.
Manufacturing ramp for MAGiC targets 500/month by year end; winding down J&J relationship.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.